Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Other Non-Current Liabilities (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $96.6 million as the latest value for Q3 2025.

  • Quarterly Other Non-Current Liabilities rose 3113.71% to $96.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $96.6 million through Sep 2025, up 3113.71% year-over-year, with the annual reading at $978000.0 for FY2023, 55.85% down from the prior year.
  • Other Non-Current Liabilities hit $96.6 million in Q3 2025 for Immunocore Holdings, up from $84.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $96.6 million in Q3 2025 to a low of $978000.0 in Q4 2023.
  • Historically, Other Non-Current Liabilities has averaged $31.6 million across 4 years, with a median of $2.6 million in 2024.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 43.62% in 2023 and later surged 3919.15% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $1.7 million in 2022, then tumbled by 43.62% to $978000.0 in 2023, then surged by 207.36% to $3.0 million in 2024, then soared by 3113.71% to $96.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for IMCR at $96.6 million in Q3 2025, $84.0 million in Q2 2025, and $62.5 million in Q1 2025.